Now live: Pro — the full 13F research suite for serious investorsSee pricing →
DAFNA Capital Management LLC

Q1 2024 · 13F-HR

DAFNA Capital Management LLCholdings as filed

Filed 2024-05-15 · accession 0001389932-24-000012

$439.3M
Reported value
72
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
78464A870XBISPDR S&P BIOTECH ETF$40.9M9.31%431,215CommonSOLE
85916J409STXSSTEREOTAXIS INC$35.7M8.13%13,680,554CommonSOLE
23282W605CYTKCYTOKINETICS INC$27.9M6.35%398,100CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$19.6M4.46%446,341CommonSOLE
N5749R1002GHMERUS N V$17.1M3.89%378,995CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$16.5M3.76%511,894CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$15.9M3.62%194,117CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$15.7M3.57%659,574CommonSOLE
464287556IBBISHARES NASDAQ BIOTECH INDX$14.1M3.20%102,500CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$14.0M3.18%92,472CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$11.8M2.68%273,739CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$11.0M2.51%666,463CommonSOLE
09627Y1092655787DBLUEPRINT MEDICINES CORP$10.1M2.31%106,763CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$9.9M2.25%71,615CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$9.6M2.18%806,973CommonSOLE
875372203TNDMTANDEM DIABETES CARE INC$9.1M2.08%258,208CommonSOLE
252131107DXCMDEXCOM INC$9.1M2.07%65,552CommonSOLE
50127T109KURAKURA ONCOLOGY INC$8.8M2.00%412,663CommonSOLE
04963C209ATRCATRICURE INC$8.2M1.88%271,029CommonSOLE
61775R105MORFUSDMORPHIC HOLDING INC$8.2M1.86%231,748CommonSOLE
05463X106AXGNAXOGEN INC$7.6M1.72%935,894CommonSOLE
G1110E107BHVNBIOHAVEN LTD$6.5M1.48%118,730CommonSOLE
901384107TSVT*2SEVENTY BIO INC$6.4M1.47%1,204,051CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$5.6M1.27%306,197CommonSOLE
014442107ALECALECTOR INC$5.5M1.25%912,928CommonSOLE
15673T100IPSCCENTURY THERAPEUTICS INC$5.5M1.24%1,307,407CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$5.0M1.13%656,373CommonSOLE
04351PAD3ASND 2.25 04/01/28ASCENDIS PHARMA A/S$4.6M1.05%4,000,000CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$4.5M1.02%67,754CommonSOLE
03969F109RCUSARCUS BIOSCIENCES INC$4.4M1.00%231,717CommonSOLE
36315X101LKFTGALAPAGOS NV$4.2M0.95%130,175CommonSOLE
46489V104ISREURPERSPECTIVE THERAPEUTICS INC$3.7M0.84%3,103,644CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$3.6M0.82%709,500CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$3.1M0.72%223,265CommonSOLE
75915K309RGLSREGULUS THERAPEUTICS INC$3.1M0.70%1,070,548CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC$3.0M0.69%122,200CommonSOLE
004397105ARAYACCURAY INC$3.0M0.69%1,222,358CommonSOLE
45784P101PODDINSULET CORP$2.7M0.62%15,900CommonSOLE
74276L105PRCTPROCEPT BIOROBOTICS CORP$2.7M0.62%54,995CommonSOLE
M68830112MDWDMEDIWOUND LTD$2.7M0.61%188,753CommonSOLE
82835W108SPRYARS PHARMACEUTICALS INC$2.4M0.56%239,194CommonSOLE
03843E104AQSTAQUESTIVE THERAPEUTICS INC$2.1M0.48%500,000CommonSOLE
N71542109PRQRPROQR THERAPEUTICS N V$2.1M0.47%905,582CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$2.0M0.46%243,210CommonSOLE
53566P109LCTXLINEAGE CELL THERAPEUTICS IN$2.0M0.46%1,366,308CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$2.0M0.45%145,000CommonSOLE
869367102SUTRO BIOPHARMA INC$1.9M0.43%334,079CommonSOLE
45780L104INGNINOGEN INC$1.7M0.38%208,790CommonSOLE
38341P102GOSSGOSSAMER BIO INC$1.7M0.38%1,409,262CommonSOLE
10501L106BWAYBRAINSWAY LTD$1.6M0.36%297,655CommonSOLE
09075V102BNTXBIONTECH SE$1.6M0.36%17,000CommonSOLE
N44445109IMTXIMMATICS NV$1.5M0.35%145,000CommonSOLE
64131A105STIMNEURONETICS INC$1.5M0.34%313,717CommonSOLE
007002108TORCEURADICET BIO INC$1.4M0.32%600,000CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$1.4M0.31%216,667CommonSOLE
00445A100ACELYRIN INC$1.4M0.31%202,587CommonSOLE
46565G1045E7ITEOS THERAPEUTICS INC$1.3M0.31%98,560CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$1.2M0.26%90,000CommonSOLE
M25722105CGENCOMPUGEN LTD$1.1M0.25%430,202CommonSOLE
45258J102IMVTIMMUNOVANT INC$950,4310.22%29,416CommonSOLE
004890109ACRVACRIVON THERAPEUTICS INC$939,1600.21%131,351CommonSOLE
03836J201APREAPREA THERAPEUTICS INC$917,6940.21%137,174CommonSOLE
M8001Q126PYPDPOLYPID LTD$853,0520.19%185,446CommonSOLE
87184Q206SYRSSYROS PHARMACEUTICALS INC$726,7980.17%135,850CommonSOLE
00653A107ADAPYADAPTIMMUNE THERAPEUTICS PLC$538,8810.12%341,064CommonSOLE
574795100MASIMASIMO CORP$440,5500.10%3,000CommonSOLE
64157F103NVROEURNEVRO CORP$404,3200.09%28,000CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$290,9440.07%192,678CommonSOLE
92673K108VIGLVIGIL NEUROSCIENCE INC$244,8890.06%71,815CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$231,4260.05%116,882CommonSOLE
84833T103SPROSPERO THERAPEUTICS INC$215,0000.05%125,000CommonSOLE
02157Q109ANROALTO NEUROSCIENCE INC$153,5000.03%10,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.